ResearcherUniversity of LiverpoolNo recent work listed
Karen Aughton
Matched on ORCID iD 0000-0002-5184-5789; OpenAlex author ID A5072002010. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper
Papers 4
- Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. First author DOI 10.3390/cimb45030164↗
- hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
- Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- William Greenhalf · 4 shared papers, 2018–2023 · strength 0.39
- Paper Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. DOI 10.3390/cimb45030164↗
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Eithne Costello · 4 shared papers, 2018–2023 · strength 0.39
- Paper Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. DOI 10.3390/cimb45030164↗
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Alan Anthoney · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- David Goldstein · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Nils O. Elander · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Paula Ghaneh · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Bengt L. G. Glimelius · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Daniel H. Palmer · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Niall Christopher Tebbutt · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- John P. Neoptolemos · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Julia V. Mayerle · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Markus M. Lerch · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Juan W. Valle · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Christopher Michael Halloran · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Richard Charnley · 3 shared papers, 2018–2021 · strength 0.21
- Paper hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. DOI 10.3390/cancers13225758↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Victoria E. Shaw · 1 shared paper, 2023 · strength 0.18
- Robert Ferguson · 1 shared paper, 2023 · strength 0.18
- Markus Wolfgang Büchler · 2 shared papers, 2018–2021 · strength 0.15
- Christos Dervenis · 2 shared papers, 2018 · strength 0.11
- Attila Oláh · 2 shared papers, 2018 · strength 0.11
- Thilo Hackert · 1 shared paper, 2021 · strength 0.09
- David Cunningham · 1 shared paper, 2021 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.